7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

Metabolic bone diseases encompass a diverse spectrum of skeletal remodeling disorders characterized by abnormal bone mineral density (BMD), disrupted microarchitectural integrity, or defective calcium-phosphate mineralization. In the United States, osteoporosis affects over 10 million adults, with an additional 44 million exhibiting osteopenia (low bone mass). Fragility fractures—particularly of the proximal femur (hip), vertebrae, and distal radius (Colles' fracture)—are major drivers of functional disability, permanent loss of independent living, nursing home admissions, and excess mortality in older adults. Approximately 20–30% of geriatric patients who sustain an osteoporotic hip fracture die within 12 months from secondary complications.

For the AGPCNP, board certification requires expertise in bone remodeling biology, DEXA densitometry interpretation, FRAX clinical risk calibration, sequential and anabolic pharmacotherapy selection, atypical fracture monitoring, and parathyroid axis diagnostic algorithms.

---

1. Bone Remodeling Biology & Calcium-Phosphate Homeostasis

+---------------------------------------------------------------------------------------------------+
|                         BONE REMODELING & CELLULAR REGULATORY CIRCUITS                            |
|                                                                                                   |
|   [OSTEOBLASTS] (Bone Formers)          [OSTEOCLASTS] (Bone Resorbers)     [OSTEOCYTES] (Sensors) |
|   - Mesenchymal stem cell origin        - Hematopoietic / Macrophage       - Entrapped osteoblasts|
|   - Synthesizes Type 1 Collagen osteoid - Secretes Hydrochloric Acid and   - Mechanosensors that  |
|   - Expresses **RANKL** and **OPG**     Cathepsin K to dissolve matrix     coordinate remodeling  |
|                                         - Expresses **RANK** receptors     - Secretes **Sclerostin|
|                                                                                                   |
|   [THE RANK / RANKL / OSTEOPROTEGERIN (OPG) AXIS]                                                 |
|   - **RANKL** (Receptor Activator of Nuclear Factor-$\kappa$B Ligand) on osteoblasts binds        |
|     **RANK** on osteoclast precursors $\rightarrow$ drives osteoclast differentiation and bone   |
|     resorption.                                                                                   |
|   - **Osteoprotegerin (OPG)** is a soluble decoy receptor produced by osteoblasts that binds      |
|     RANKL, blocking its interaction with RANK $\rightarrow$ inhibits bone resorption.             |
|   - **Estrogen** stimulates OPG production and induces osteoclast apoptosis; estrogen loss at    |
|     menopause leads to uninhibited RANKL expression and rapid, accelerated osteoclastic resorption.|
+---------------------------------------------------------------------------------------------------+

The Calcium-Phosphate Regulatory Triad

Extracellular ionized calcium is maintained within a narrow physiological window ($8.5\text{--}10.5\text{ mg/dL}$) by the integrated actions of three primary hormones:

1. Parathyroid Hormone (PTH): Synthesized by parathyroid chief cells in response to hypocalcemia sensed by the calcium-sensing receptor (CaSR).
   • Kidney: Increases distal tubular calcium reabsorption; inhibits proximal tubular phosphate reabsorption (promotes phosphaturia); upregulates renal $1\alpha$-hydroxylase (CYP27B1) to convert 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D ($1,25[\text{OH}]_2\text{D}_3$ / Calcitriol).
   • Bone: Chronically stimulates osteoblasts to upregulate RANKL, indirectly accelerating osteoclastic bone resorption and mobilizing calcium and phosphate into the circulation.
   • Intestine: Indirectly increases enterocyte calcium and phosphate absorption via calcitriol.
2. 1,25-Dihydroxyvitamin D (Calcitriol): Active steroid hormone that enhances enterocyte calcium (via TRPV6 channels and calbindin-D9k) and phosphate absorption in the small intestine, facilitates mineralization of osteoid, and provides negative feedback suppression on PTH transcription.
3. Calcitonin: Synthesized by thyroid parafollicular C-cells in response to hypercalcemia; directly binds osteoclast calcitonin receptors to inhibit bone resorption and promotes renal calcium excretion (minor physiological role in humans).

---

2. Osteopenia & Osteoporosis: Diagnostic Classification, DEXA & FRAX

+---------------------------------------------------------------------------------------------------+
|                         DEXA SCAN DIAGNOSTIC CRITERIA (WHO DEFINITIONS)                           |
|                                                                                                   |
|   DIAGNOSTIC CATEGORY          T-SCORE THRESHOLD (BMD vs. Peak Young Adult Reference)             |
|   ---------------------------------------------------------------------------------------------   |
|   NORMAL BONE MINERAL DENSITY  **T-score >= -1.0 SD**                                             |
|   OSTEOPENIA (Low Bone Mass)   **T-score between -1.0 and -2.5 SD** (-1.1 to -2.4 SD)             |
|   OSTEOPOROSIS                 **T-score <= -2.5 SD** (at Lumbar Spine, Femoral Neck,             |
|                                Total Hip, or 33% Radius)                                          |
|   SEVERE / ESTABLISHED         **T-score <= -2.5 SD PLUS ONE OR MORE FRAGILITY FRACTURES**        |
|   OSTEOPOROSIS                                                                                    |
+---------------------------------------------------------------------------------------------------+

Critical Technical Nuances in Densitometry:

• T-Score vs. Z-Score:
  • T-Score: Compares the patient's BMD to a young, healthy sex-matched reference population at peak bone mass (age 20–29). Used diagnostically for postmenopausal women and men aged $\ge 50$ years.
  • Z-Score: Compares the patient's BMD to an age-, sex-, and race/ethnicity-matched reference population. Used for premenopausal women, men $<50$ years, and children. A Z-score $\le -2.0\text{ SD}$ is defined as "below the expected range for age" and mandates an exhaustive search for secondary causes of osteoporosis.
• Anatomical Scan Sites: Standard DEXA evaluates the Lumbar Spine (L1–L4), Femoral Neck, and Total Hip. If spine or hip sites cannot be reliably interpreted (e.g., severe degenerative osteoarthritis, prior bilateral total hip arthroplasty, severe scoliosis, or primary hyperparathyroidism), the non-dominant Forearm (33% / one-third Radius) is scanned.
• Osteoarthritis Artifact: Severe lumbar spondylosis, osteophytes, and aortic vascular calcifications falsely elevate lumbar spine BMD. In older adults, the femoral neck and total hip provide the most reliable prognostic values.

Population Screening Guidelines (USPSTF, NOF & AACE):

• Universal Screening:
  • All women aged $\ge 65$ years regardless of clinical risk factors (USPSTF Grade B).
  • All men aged $\ge 70$ years (NOF/BHOF and Endocrine Society guidelines).
• Risk-Based Screening (Age <65 in Postmenopausal Women; Age 50–69 in Men): Screen individuals who possess clinical risk factors for accelerated bone loss or fracture:
  • Previous fragility fracture sustained in adulthood after age 50.
  • Chronic systemic glucocorticoid therapy ($\ge 5\text{ mg/day}$ prednisone equivalent for $\ge 3\text{ months}$).
  • Low body weight ($\text{BMI} < 20\text{ kg/m}^2$ or body weight $< 127\text{ lbs} [57.6\text{ kg}]$).
  • Parental history of hip fracture.
  • Current cigarette smoking.
  • High alcohol consumption ($\ge 3\text{ standard drinks/day}$).
  • Rheumatoid arthritis or other chronic inflammatory arthropathies.
  • Secondary causes: Primary hyperparathyroidism, untreated hyperthyroidism, hypogonadism (e.g., androgen deprivation therapy for prostate cancer, aromatase inhibitors for breast cancer), celiac disease / malabsorption, bariatric surgery, chronic PPI or antiepileptic therapy.

The FRAX (Fracture Risk Assessment Tool) & Treatment Thresholds

FRAX is an algorithm developed by the World Health Organization that integrates femoral neck BMD with clinical risk factors to calculate a patient's 10-Year Probability of a Major Osteoporotic Fracture (clinical spine, hip, forearm, or proximal humerus) and 10-Year Probability of a Hip Fracture.

+---------------------------------------------------------------------------------------------------+
|                         PHARMACOLOGICAL TREATMENT INITIATION THRESHOLDS                           |
|                                                                                                   |
|   Initiate pharmacological anti-osteoporotic therapy in postmenopausal women and men >=50 with:   |
|                                                                                                   |
|   1. A HISTORY OF HIP OR VERTEBRAL FRAGILITY FRACTURE (Clinical or asymptomatic morphometric      |
|      vertebral compression fracture on imaging), REGARDLESS of BMD T-score.                       |
|                                                                                                   |
|   2. DEXA T-SCORE <= -2.5 at the Femoral Neck, Total Hip, Lumbar Spine, or 33% Radius.            |
|                                                                                                   |
|   3. OSTEOPENIA (T-score between -1.0 and -2.5) PLUS FRAX 10-YEAR PROBABILITY OF:                 |
|      * MAJOR OSTEOPOROTIC FRACTURE >= 20%, OR                                                     |
|      * HIP FRACTURE >= 3.0%                                                                       |
+---------------------------------------------------------------------------------------------------+

---

3. Comprehensive Pharmacotherapy: Antiresorptive vs. Anabolic Protocols

+---------------------------------------------------------------------------------------------------+
|                         OSTEOPOROSIS THERAPEUTIC CLASSIFICATION                                  |
|                                                                                                   |
|   [ANTIRESORPTIVE AGENTS] (Inhibit Osteoclastic Resorption)                                       |
|   • Oral Bisphosphonates: Alendronate (70 mg/wk), Risedronate (35 mg/wk), Ibandronate (150 mg/mo) |
|   • IV Bisphosphonates: Zoledronic Acid (5 mg IV once yearly)                                     |
|   • Monoclonal RANKL Inhibitor: Denosumab (60 mg SubQ every 6 months)                             |
|   • Selective Estrogen Receptor Modulator (SERM): Raloxifene (60 mg daily)                        |
|                                                                                                   |
|   [ANABOLIC / BONE-BUILDING AGENTS] (Stimulate Osteoblastic Formation)                            |
|   • Recombinant PTH Analogs: Teriparatide (20 mcg SubQ daily), Abaloparatide (80 mcg SubQ daily)  |
|   • Monoclonal Sclerostin Inhibitor: Romosozumab (210 mg SubQ monthly x 12 months)               |
+---------------------------------------------------------------------------------------------------+

Comprehensive Osteoporosis Drug Comparison Matrix

Oral Bisphosphonate Administration Rules & Drug Holidays

• Strict Administration Protocol: Take first thing in the morning with a full 8 ounces of plain tap water (not mineral water, coffee, juice, or tea) at least 30 minutes (60 minutes for ibandronate) before the first food, beverage, or other medications. The patient must remain completely upright (sitting or standing) for at least 30 minutes and avoid reclining to prevent chemical pill-induced esophagitis and esophageal stricture formation.
• The Bisphosphonate "Drug Holiday" Protocol: Because bisphosphonates incorporate into the mineralized skeletal matrix and persist for years, long-term continuous use (>5 years) over-suppresses bone turnover, increasing the risk of Atypical Subtrochanteric Femur Fractures (AFF) (characterized by prodromal dull thigh/groin aching, lateral cortical thickening/beaking, and transverse fracture lines) and Osteonecrosis of the Jaw (ONJ).
  • Low-to-Moderate Fracture Risk: Initiate a drug holiday after 5 years of oral bisphosphonates (or 3 years of IV zoledronic acid). Re-evaluate BMD every 2–3 years.
  • High Fracture Risk (T-score remains $\le -2.5$ at hip, or prior fragility fracture): Continue therapy up to 10 years (or 6 years of IV zoledronic acid) or transition to an alternative agent.

[!WARNING] The Denosumab Discontinuation Trap: Unlike bisphosphonates, Denosumab does NOT incorporate into the bone matrix. Its antiresorptive effects dissipate rapidly within 6 months of a missed dose, triggering a profound rebound surge in osteoclastic activity with rapid loss of all gained BMD and a clustering of multiple spontaneous vertebral compression fractures. If denosumab must be stopped, the patient MUST immediately be transitioned to an IV or oral bisphosphonate (e.g., Zoledronic acid infusion 6 months after the final denosumab dose) to preserve bone density.

---

4. Primary, Secondary & Tertiary Hyperparathyroidism

+---------------------------------------------------------------------------------------------------+
|                         HYPERPARATHYROIDISM SPECTRUM DECISION MATRIX                              |
|                                                                                                   |
|   FEATURE               PRIMARY (PHPT)              SECONDARY (SHPT)        TERTIARY (THPT)       |
|   ---------------------------------------------------------------------------------------------   |
|   Primary Etiology      Solitary Adenoma (85%)      • Chronic Kidney Disease• Longstanding SHPT   |
|                         Hyperplasia (15%, MEN 1/2A)   (loss of 1a-hydroxylase; (End-stage ESRD / |
|                         Parathyroid Carcinoma (<1%)   phosphate retention)    post-renal transplant)|
|                                                     • Severe Vit D Defic.   Autonomous nodules    |
|   Serum Intact PTH      **ELEVATED / INAPPROPRIATE** **ELEVATED** (Compensatory) **MARKETLY HIGH**   |
|   Serum Total / Ionized **HIGH** ($>10.5\text{ mg/dL}$) **LOW OR NORMAL**          **HIGH**               |
|   Calcium                                                                                         |
|   Serum Phosphate       **LOW OR LOW-NORMAL**       **HIGH** (in CKD) or    **HIGH OR NORMAL**    |
|                         (Phosphaturia)              **LOW** (in Vit D def)                        |
|   24-Hour Urine Calcium **HIGH OR NORMAL**          **LOW** (Renal failure) Variable              |
|                         (Excludes FHH)                                                            |
|   Definitive Management **Parathyroidectomy**       Calcitriol, Phosphate   Subtotal              |
|                         (or Cinacalcet for non-op)  binders, Cinacalcet     Parathyroidectomy     |
+---------------------------------------------------------------------------------------------------+

A. Primary Hyperparathyroidism (PHPT)

• The Classic Clinical Mnemonic: "Bones, Stones, Abdominal Groans, Psychic Moans, and Fatigue Overtones"
  • Bones: Osteopenia, accelerated cortical bone loss (prominent T-score reduction at the 33% distal radius), bone pain, and in severe advanced cases, Osteitis Fibrosa Cystica (subperiosteal bone resorption on phalangeal radiograms, "salt-and-pepper" skull, brown osteoclastomas).
  • Stones: Recurrent nephrolithiasis (calcium oxalate and calcium phosphate stones), nephrocalcinosis, polyuria, polydipsia (nephrogenic DI effect from hypercalcemia).
  • Abdominal Groans: Severe constipation, nausea, anorexia, peptic ulcer disease (calcium stimulates gastric acid secretion), acute pancreatitis (calcium activates pancreatic trypsinogen).
  • Psychic Moans: Depression, cognitive slowing ("brain fog"), anxiety, memory deficits, insomnia, psychosis, delirium, proximal muscle weakness.
• Diagnostic Rule-Out: Familial Hypocalciuric Hypercalcemia (FHH):
  • Autosomal dominant inactivating mutation in the calcium-sensing receptor (CaSR). Characterized by lifelong mild hypercalcemia, normal or mildly elevated PTH, but very low 24-hour urinary calcium excretion with a Calcium-to-Creatinine Clearance Ratio (CCCR) $<0.01$ (in PHPT, CCCR $>0.02$).
  • Clinical Importance: FHH is completely benign and does NOT respond to parathyroidectomy. Parathyroid surgery is contraindicated!

Consensus Guidelines for Parathyroidectomy in Asymptomatic PHPT

Parathyroidectomy is curative in >95% of cases. In asymptomatic PHPT, surgery is indicated if the patient meets ANY ONE of the following criteria (The 2022 International Workshop Criteria):

1. Serum Calcium: $>1.0\text{ mg/dL}$ above the upper limit of normal ($>11.5\text{ mg/dL}$).
2. Skeletal Involvement: DEXA T-score $\le -2.5$ at the lumbar spine, femoral neck, total hip, or 33% radius; or evidence of a vertebral fragility fracture on spine imaging.
3. Renal Involvement: Estimated GFR $<60\text{ mL/min/1.73 m}^2$; or 24-hour urinary calcium excretion $>400\text{ mg/day}$ with kidney stone risk factors; or presence of nephrolithiasis / nephrocalcinosis on renal ultrasound/CT.
4. Age: Age $<50$ years (patients will accrue lifetime complications without intervention).

---

5. Hypocalcemia, Hypoparathyroidism & Paget's Disease of Bone

+---------------------------------------------------------------------------------------------------+
|                         NEUROMUSCULAR SIGNS OF HYPOCALCEMIA                                       |
|                                                                                                   |
|   [CHVOSTEK'S SIGN]                                 [TROUSSEAU'S SIGN]                            |
|   - Technique: Tap the facial nerve anterior to     - Technique: Inflate a sphygmomanometer cuff  |
|     the earlobe / zygomatic arch.                     above SBP for 3 minutes.                    |
|   - Positive Response: Ipsilateral twitching of the - Positive Response: Carpopedal spasm        |
|     facial muscles (lip, nose, orbicularis oculi).    (flexion of wrist/MCP joints, extension     |
|   - Sensitivity: Moderate (~70-80%); present in      of IP joints, adduction of thumb: "Main      |
|     10-15% of healthy individuals.                    d'accoucheur").                             |
|                                                     - Sensitivity: High (>90%); highly specific!  |
+---------------------------------------------------------------------------------------------------+

A. Hypoparathyroidism

• Etiology: Overwhelmingly iatrogenic following inadvertent removal, devascularization, or damage to parathyroid glands during total thyroidectomy, central neck dissection, or parathyroid surgery. Rare causes: Autoimmune Polyglandular Syndrome Type 1 (APS-1), severe hypomagnesemia (inhibits PTH release and induces end-organ resistance).
• Diagnostic Profile: Low serum corrected calcium, elevated serum phosphate, low/undetectable intact PTH, with normal renal function.
• Therapy: Oral calcium carbonate/citrate ($1,000\text{--}3,000\text{ mg/day}$) + Calcitriol (0.25–1.0 mcg/day) to enhance intestinal calcium absorption. Target low-normal serum calcium ($8.0\text{--}8.5\text{ mg/dL}$) to avoid hypercalciuria and nephrocalcinosis (because lacking PTH leads to defective renal calcium reabsorption).

B. Paget's Disease of Bone (Osteitis Deformans)

• Pathophysiology: Focal skeletal disorder characterized by initial chaotic, excessive osteoclastic bone resorption followed by disorganized, highly vascular, structurally weak osteoblastic bone formation (mosaic "woven bone" pattern).
• Hallmark Clinical Features: Frequently asymptomatic; localized bone pain (pelvis, spine, femur, skull), progressive skull enlargement ("hat size increasing"), sensorineural hearing loss (temporal bone compression of CN VIII), bowed shins / sabre tibia, osteoarthritis, and high-output congestive heart failure (due to extensive arteriovenous shunts in hypervascular pagetic bone). Rare transformation to osteosarcoma (<1%).
• Diagnostic Labs & Radiography: Markedly elevated isolated Serum Alkaline Phosphatase (ALP) with completely normal serum calcium, phosphate, and PTH. X-rays reveal "cotton-wool" skull, cortical thickening, and osteolytic wedge-shaped lesions.
• Treatment of Choice: IV Zoledronic Acid (5 mg single dose) produces rapid, sustained biochemical remission; oral alendronate (40 mg daily x 6 months) as second-line.

---

6. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Universal Bone Screening Age: All women age >=65 and all men age >=70 MUST be screened with    |
|     DEXA regardless of clinical risk factors.                                                     |
|                                                                                                   |
|   - The FRAX Thresholds: Treat Osteopenia (T-score -1.0 to -2.5) if 10-year Major Osteoporotic    |
|     Fracture risk is >=20% OR 10-year Hip Fracture risk is >=3.0%.                                 |
|                                                                                                   |
|   - Bisphosphonate Upright Rule: Patients MUST remain sitting/standing upright for >=30 minutes   |
|     after swallowing oral bisphosphonate with 8 oz plain water to prevent esophageal ulcers.      |
|                                                                                                   |
|   - Denosumab Rebound Warning: NEVER abruptly discontinue Denosumab without immediately bridging  |
|     to an IV/oral bisphosphonate! Rebound osteoclast surges cause multiple vertebral fractures.   |
|                                                                                                   |
|   - PHPT Distal Radius Scanning: Hyperparathyroidism preferentially resorbs cortical bone; always |
|     include the 33% (one-third) distal radius in densitometry when evaluating hyperparathyroidism. |
|                                                                                                   |
|   - Asymptomatic PHPT Surgery Cutoff: Age <50 years is an automatic Class 1 indication for        |
|     parathyroidectomy even in completely asymptomatic primary hyperparathyroidism.                |
+---------------------------------------------------------------------------------------------------+